MRK

Over the past six months, Merck & Co., Inc. (MRK) stock has shown notable movements. As of October 8, 2026, the stock price increased by 64.89% over the last 12 months, with a year-to-date return of 35.41%, closing at $142.66. Recent performance includes a 1.27% rise compared to the previous week, a 2.26% fall over the last month, and a 0.62% gain in the past four weeks. The stock reached a 54-year high of $147.00 on August 19, 2026, but also experienced lows, hitting $143.36 on September 15, 2026, and $142.30 on October 5, 2026. Merck's Q1 CY2026 earnings, reported on April 30, 2026, exceeded analyst expectations with revenue up 4.9% year-over-year to $16.29 billion and a non-GAAP loss of $0.13 per share, driven by strong oncology and animal health sales and new product launches. The company also slightly raised its full-year revenue guidance. In Q2 2026, Merck reported $16.6 billion in revenue, with Keytruda sales growing by 4%.